‘Beyond Structure, Predicting Function’<\/b><\/p>\n
SHANGHAI<\/span>, Dec. 26, 2024 \/PRNewswire\/ — Recently, Shanghai Matwings Technology Co., Ltd. (‘Matwings’), a global leader in AI-driven protein design, announced the successful completion of Series A funding rounds, raising tens of millions of USD, led by Qiming Venture Partners.<\/span><\/p>\n Matwings is pioneering a new frontier in protein engineering with its proprietary AI-based general protein design platform, AccelProtein\u2122, which directly predicts protein functionality beyond the structural data. By predicting functionality, AccelProtein\u2122 offers a new approach for acquiring high-functioning proteins.<\/p>\n AccelProtein\u2122 is built on the Pro-PRIME model, a breakthrough developed by a collaborative team led by Professor Liang Hong<\/span> at Shanghai Jiao Tong University. After years of research focused on data collection, curation, and optimization, the team developed the Pro-series – an AI framework for protein design. Their work, titled “A General Temperature-Guided Language Model to Design Proteins of Enhanced Stability and Activity”<\/a><\/i>\u00a0was recently published in Science Advances<\/i>.<\/p>\n A featured case of AccelProtein\u2122’s impact is the design of a specialized Glycosyltransferase enzyme, which is used in the production of EPS-G7, a core material for pancreatitis screening. Within just 4 months, Matwings increased the enzyme’s total glycosylation activity by 7 times, enhanced product specificity from 60% to 98%, and reduced hydrolytic activity by 33%. These improvements cut down the cost of EPS-G7 by 90%.<\/p>\n In another application, Matwings successfully engineered a super alkali-resistant affinity ligand (a nanobody) for affinity chromatography, improving alkali resistance by 3 folds, binding capacity over 100%, and heat stability by 8\u2103. This innovation saved millions of USD in CMC costs for a Matwings client. Additionally, scale-up production to 5000L has been successfully completed. Such advancement enables low-cost affinity chromatography purification a viable option for a wide range of biologics, bringing more cost-effective solutions for drug production.<\/p>\n Since 2021, Matwings has successfully delivered over 30 protein-engineering and enzyme-mining projects either proprietary (e.g., Enterokinase, Carboxypeptidase B, KEX2 Protease, Maltogenic Amylase, Subtilisin, Protein A, PETase, T7 RNA Polymerase, and phi29 DNA Polymerase) and co-developed with our stakeholders. These projects span across various applications, including drug innovation, in vitro diagnostics, nutrition and healthcare, food and beverage, and green energy.<\/p>\n About Matwings<\/b><\/p>\n Matwings, founded in 2021 by an elite team from Shanghai Jiao Tong University, is one of the earliest companies to focus on AI protein models.<\/p>\n Matwings is dedicated to moving beyond directed evolution methods to design and engineer functionally optimized proteins by leveraging a proprietary, pre-trained, AI-based general protein design platform with 780 million curated full-length protein sequence data, including nearly 500 million private data.<\/span><\/p>\n This cutting-edge technology platform, AccelProtein\u2122, enables us to engineer proteins and uncover or de novo design novel proteins with significantly improved properties, including stability, activity, affinity, yield, etc.<\/p>\n To date, Matwings has successfully engineered more than 30 proteins either proprietary or co-developed with its stakeholders, and more than 40 ongoing projects<\/span> across various applications in pharmaceutical industries and synthetic biology industries, e.g.\u00a0 key enzymes and proteins for CMC, innovative Biologics, synthetic biology and more.<\/p>\n Matwings is actively seeking global partnerships to jointly develop and commercialize new products.<\/span><\/p>\n Contact Information:<\/b> <\/p>\n ‘Beyond Structure, Predicting Function’<\/b><\/p>\n SHANGHAI<\/span>, Dec. 26, 2024 \/PRNewswire\/ — Recently, Shanghai Matwings Technology Co., Ltd. (‘Matwings’), a global leader in AI-driven protein design, announced the successful completion of Series A funding rounds, raising tens of millions of USD, led by Qiming Venture Partners.<\/span><\/p>\n Matwings is pioneering a new frontier in protein engineering with its proprietary AI-based general protein design platform, AccelProtein\u2122, which directly predicts protein functionality beyond the structural data. By predicting functionality, AccelProtein\u2122 offers a new approach for acquiring high-functioning proteins.<\/p>\n AccelProtein\u2122 is built on the Pro-PRIME model, a breakthrough developed by a collaborative team led by Professor Liang Hong<\/span> at Shanghai Jiao Tong University. After years of research focused on data collection, curation, and optimization, the team developed the Pro-series – an AI framework for protein design. Their work, titled “A General Temperature-Guided Language Model to Design Proteins of Enhanced Stability and Activity”<\/a><\/i>\u00a0was recently published in Science Advances<\/i>.<\/p>\n A featured case of AccelProtein\u2122’s impact is the design of a specialized Glycosyltransferase enzyme, which is used in the production of EPS-G7, a core material for pancreatitis screening. Within just 4 months, Matwings increased the enzyme’s total glycosylation activity by 7 times, enhanced product specificity from 60% to 98%, and reduced hydrolytic activity by 33%. These improvements cut down the cost of EPS-G7 by 90%.<\/p>\n In another application, Matwings successfully engineered a super alkali-resistant affinity ligand (a nanobody) for affinity chromatography, improving alkali resistance by 3 folds, binding capacity over 100%, and heat stability by 8\u2103. This innovation saved millions of USD in CMC costs for a Matwings client. Additionally, scale-up production to 5000L has been successfully completed. Such advancement enables low-cost affinity chromatography purification a viable option for a wide range of biologics, bringing more cost-effective solutions for drug production.<\/p>\n Since 2021, Matwings has successfully delivered over 30 protein-engineering and enzyme-mining projects either proprietary (e.g., Enterokinase, Carboxypeptidase B, KEX2 Protease, Maltogenic Amylase, Subtilisin, Protein A, PETase, T7 RNA Polymerase, and phi29 DNA Polymerase) and co-developed with our stakeholders. These projects span across various applications, including drug innovation, in vitro diagnostics, nutrition and healthcare, food and beverage, and green energy.<\/p>\n About Matwings<\/b><\/p>\n Matwings, founded in 2021 by an elite team from Shanghai Jiao Tong University, is one of the earliest companies to focus on AI protein models.<\/p>\n Matwings is dedicated to moving beyond directed evolution methods to design and engineer functionally optimized proteins by leveraging a proprietary, pre-trained, AI-based general protein design platform with 780 million curated full-length protein sequence data, including nearly 500 million private data.<\/span><\/p>\n This cutting-edge technology platform, AccelProtein\u2122, enables us to engineer proteins and uncover or de novo design novel proteins with significantly improved properties, including stability, activity, affinity, yield, etc.<\/p>\n To date, Matwings has successfully engineered more than 30 proteins either proprietary or co-developed with its stakeholders, and more than 40 ongoing projects<\/span> across various applications in pharmaceutical industries and synthetic biology industries, e.g.\u00a0 key enzymes and proteins for CMC, innovative Biologics, synthetic biology and more.<\/p>\n Matwings is actively seeking global partnerships to jointly develop and commercialize new products.<\/span><\/p>\n Contact Information:<\/b> <\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-15750","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/15750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15750"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/15750\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Email: info@matwings.com<\/a>
Website: https:\/\/www.matwings.com\/en\/<\/a>\u00a0
Tel: +86 158 2106 5410
Paper Link: https:\/\/www.science.org\/doi\/10.1126\/sciadv.adr2641<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"
Email: info@matwings.com<\/a>
Website: https:\/\/www.matwings.com\/en\/<\/a>\u00a0
Tel: +86 158 2106 5410
Paper Link: https:\/\/www.science.org\/doi\/10.1126\/sciadv.adr2641<\/a>\u00a0<\/p>\n